Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03349892 · ClinicalTrials.gov registry record · NA
Stereotactic Ablative Radiotherapy for Refractory Ventricular Tachycardia
A NA study, sponsored by University of California, Los Angeles.
- Completed
- Registry status
- NA
- Development phase
- 1
- Enrollment target
NCT03349892: Completed NA study, sponsored by University of California, Los Angeles.
NCT03349892 is a NA study that has completed, run by University of California, Los Angeles. The registered enrollment target is 1 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03349892, a NA study, has completed, sponsored by University of California, Los Angeles.
- COMPLETED
- Registry status
- NA
- Development phase
- 1 participants
- Enrollment target
Study Summary
Single arm, phase Ib/2a dose escalation study with an expansion cohort to determine the maximal tolerated dose (MTD) for stereotactic ablative radiotherapy of targets in the cardiac myocardium and to make a preliminary assessment of the efficacy of the treatment. The dose escalation will be guided by Time-to-Event Continual Reassessment Method (TITE-CRM) to ensure more patients will be spared dose limiting toxicities and more patients will be entered on the dose level that will be chosen as minimal dose of maximal effect. This design also allows for continual accrual of patients when delayed adverse events may be observed.
Primary Outcome
ICD (implantable cardioverter defibrillator) shock free survival at six months
Interventions
- RADIATION Stereotactic Ablative Radiotherapy (SABR)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2017-04-01 |
| Est. Completion | 2019-08-06 |
| Phase | NA |
What the finished NCT03349892 record still lists
NCT03349892 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 1 intervention - of which Stereotactic Ablative Radiotherapy (SABR) is the first listed.
NCT03349892 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03349892 about?
NCT03349892 is a clinical study titled "Stereotactic Ablative Radiotherapy for Refractory Ventricular Tachycardia". Single arm, phase Ib/2a dose escalation study with an expansion cohort to determine the maximal tolerated dose (MTD) for stereotactic ablative radiotherapy of targets in the cardiac myocardium and to make a preliminary assessment of the efficacy of the treatment. The dose escalation will be guided b...
What is the current status of trial NCT03349892?
This trial is currently completed. It is a NA study. The enrollment target is 1 participants. The study started on 2017-04-01. Estimated completion is 2019-08-06.
What interventions are being tested in trial NCT03349892?
The interventions under investigation include: Stereotactic Ablative Radiotherapy (SABR) (RADIATION).
Who is sponsoring clinical trial NCT03349892?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03349892's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI